Fat infusion study aims to unlock diabetes clues
NCT ID NCT03479671
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed early-phase study tested different doses of fatty acids (Intralipid) in 9 healthy volunteers to find the dose that causes mild insulin resistance. The goal was to create a reliable model for future diabetes research. Participants received low or medium doses of fat infusion, and their insulin sensitivity was measured.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Intralipid (fatty acid infusion)
- What this could lead to
- If successful, this could help researchers design better studies on how fat affects insulin resistance, potentially leading to new diabetes treatments.
- What could go wrong
- This is a very small, early-phase study with only 9 healthy volunteers, so results may not apply to people with diabetes or other conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
9 people
The number who actually took part.
- Started
-
Jan 2020
- Finished
-
Nov 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 44 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects who are able to provide written informed consent and to comply with the procedures of the study protocol Exclusion Criteria: * History of diabetes * History of diabetes in more than one first-degree relative * Body mass index (BMI) \<19 or \>27 kg/m2 * HbA1c \>5.7% * Blood Pressure: systolic \>160 mmHg or diastolic \> 100 mmHg * Baseline hemoglobin concentration \< 11 g/dl in women and \< 12 g/dl in men * Estimated glomerular filtration rate \< 55 ml/min/1.73 m2 (calculated using the subject's measured serum creatinine and the Modification of Diet in Renal Disease \[MDRD\] study estimation formula). * Presence of soy or egg allergies (due to possible reactions with fat infusate) * For female participants: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable. * Known active alcohol or substance abuse * Use of tobacco within the previous year * Severe co-existing cardiac disease, characterized by any one of these conditions: 1. history of myocardial infarction within past 6 months; 2. history of ischemia on functional cardiac exam within the last year; 3. history of left ventricular ejection fraction \< 30%. * Persistent elevation of liver function tests \> 1.5 times normal upper limits * Hyperlipidemia (fasting LDL cholesterol \> 130 mg/dl, treated or untreated; and/or fasting triglycerides \> 200 mg/dl) * Receiving treatment for a medical condition requiring chronic use of systemic steroids, except for the use of ≤ 5 mg prednisone daily, or an equivalent physiological dose of hydrocortisone * Presence of a seizure disorder * Use of any investigational agents within 4 weeks of enrollment * Any medical condition, which in the opinion of the investigator, will interfere with the safe completion of the study * History of pancreatitis * Presence of a metal allergy (aluminum)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can a vegan diet shield police officers from heart disease?
- Can a health coach in your patient portal help you lose weight?
- Common antibiotic may boost diabetes control
- Can continuous glucose monitors safely tighten hospital blood sugar control?